MD960334A - Anticorp fibrino-specific utilizat ca agent antitrombotic - Google Patents

Anticorp fibrino-specific utilizat ca agent antitrombotic

Info

Publication number
MD960334A
MD960334A MD96-0334A MD960334A MD960334A MD 960334 A MD960334 A MD 960334A MD 960334 A MD960334 A MD 960334A MD 960334 A MD960334 A MD 960334A
Authority
MD
Moldova
Prior art keywords
fibrin
specific antibody
antithrombotic agent
antithrombotic
agent
Prior art date
Application number
MD96-0334A
Other languages
English (en)
Other versions
MD1521F2 (ro
MD1521G2 (ro
Inventor
Paul E Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of MD960334A publication Critical patent/MD960334A/ro
Publication of MD1521F2 publication Critical patent/MD1521F2/ro
Publication of MD1521G2 publication Critical patent/MD1521G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MD96-0334A 1994-02-24 1995-02-21 Metode de inhibare a formării de trombi, metode de tratament al stărilor trombotice, compoziţii farmaceutice şi trusă pentru tratamentul stărilor trombotice MD1521G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (3)

Publication Number Publication Date
MD960334A true MD960334A (ro) 1997-09-30
MD1521F2 MD1521F2 (ro) 2000-08-31
MD1521G2 MD1521G2 (ro) 2001-03-31

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0334A MD1521G2 (ro) 1994-02-24 1995-02-21 Metode de inhibare a formării de trombi, metode de tratament al stărilor trombotice, compoziţii farmaceutice şi trusă pentru tratamentul stărilor trombotice

Country Status (26)

Country Link
US (1) US5487892A (ro)
EP (1) EP0749320A4 (ro)
JP (1) JPH09509429A (ro)
KR (1) KR970701063A (ro)
CN (1) CN1146157A (ro)
AU (1) AU708897B2 (ro)
BG (1) BG62476B1 (ro)
BR (1) BR9506949A (ro)
CA (1) CA2183953A1 (ro)
CZ (1) CZ246496A3 (ro)
FI (1) FI963288A0 (ro)
GE (1) GEP20002257B (ro)
HU (1) HUT76536A (ro)
LT (1) LT4192B (ro)
LV (1) LV11784B (ro)
MD (1) MD1521G2 (ro)
MX (1) MX9603602A (ro)
NO (1) NO963497L (ro)
NZ (1) NZ281481A (ro)
PL (1) PL316005A1 (ro)
RU (1) RU2152801C2 (ro)
SG (1) SG53279A1 (ro)
SK (1) SK108496A3 (ro)
TJ (1) TJ301B (ro)
UA (1) UA41984C2 (ro)
WO (1) WO1995022986A1 (ro)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP4088328B2 (ja) * 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
AU7912887A (en) * 1986-08-25 1988-03-24 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
WO1989012690A1 (en) * 1988-06-13 1989-12-28 American Biogentic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
NZ281481A (en) 1998-07-28
MD1521F2 (ro) 2000-08-31
PL316005A1 (en) 1996-12-23
HUT76536A (en) 1997-09-29
EP0749320A1 (en) 1996-12-27
KR970701063A (ko) 1997-03-17
CA2183953A1 (en) 1995-08-31
SG53279A1 (en) 1998-09-28
EP0749320A4 (en) 1997-06-18
FI963288A7 (fi) 1996-08-23
BR9506949A (pt) 1997-09-23
BG62476B1 (bg) 1999-12-30
NO963497L (no) 1996-10-16
UA41984C2 (uk) 2001-10-15
LT96140A (en) 1997-03-25
AU708897B2 (en) 1999-08-12
RU2152801C2 (ru) 2000-07-20
JPH09509429A (ja) 1997-09-22
MX9603602A (es) 1997-05-31
FI963288L (fi) 1996-08-23
LV11784B (en) 1997-12-20
LT4192B (en) 1997-07-25
FI963288A0 (fi) 1996-08-23
WO1995022986A1 (en) 1995-08-31
AU1843495A (en) 1995-09-11
MD1521G2 (ro) 2001-03-31
BG100863A (en) 1997-08-29
CZ246496A3 (en) 1997-04-16
GEP20002257B (en) 2000-10-25
CN1146157A (zh) 1997-03-26
SK108496A3 (en) 1997-10-08
NO963497D0 (no) 1996-08-22
LV11784A (lv) 1997-06-20
TJ301B (en) 2001-08-06
HU9602337D0 (en) 1996-10-28
US5487892A (en) 1996-01-30

Similar Documents

Publication Publication Date Title
GB9420657D0 (en) Contrast agents
GB9422383D0 (en) Antibodies
GB9421013D0 (en) Roundness measuring
IL115479A0 (en) Composition for ophthalmic use
HU9601240D0 (en) Beta-adrenerg agonists
EP0500947A4 (en) Assaying agent for endotoxin
ZA951232B (en) Contrast agents
SG53279A1 (en) Fibrin-specific antibody for use as an antithrombotic agent
GB9504331D0 (en) Antithrombotic agents
GB2288520B (en) Pipeline
GB9608760D0 (en) Extensometer
ZA951618B (en) Antithrombotic agents
HUP9903852A3 (en) Process for the preparation of contrast agents
GB2292433B (en) Pipeline
PL319904A1 (en) Nitrobenzamides useful as antiarrythimic agents
EP0748333A4 (en) ANTITHROMBOTIC SUBSTANCES
GB2289108B (en) Piping
ZA951615B (en) Antithrombotic agents
ZA965962B (en) Anti-piroplasmotic agent
PL303744A1 (en) Antocorrosive agent
GB9406243D0 (en) Antibodies
GB9406222D0 (en) Huminised antibodies
IL134049A0 (en) Anti-cryptdin antibodies
PL307196A1 (en) Pharmaceutcal agent
GB9020098D0 (en) Chromatographic agent

Legal Events

Date Code Title Description
PD99 Pending application